This booklet is a guide to a man's prostate – what it is, what it does, and what can go wrong with it. It explains the three most common prostate problems, what changes to look out for, what to do if you think you have a prostate problem, and what might happen at the GP surgery.

Last updated January 2015
To be reviewed January 2017


  • Albertson PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncologica 2011;50(1):120–26
  • Allen NE, Key TJ, Appleby PN, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008;98(9):1574–81.
  • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer. 2014. Available from:
  • Arab L, Su J, Steck SE, et al. Adherence to World Cancer Research Fund/American Institute for Cancer Research Lifestyle Recommendations Reduces Prostate Cancer Aggressiveness Among African and Caucasian Americans. Nutrition and Cancer 2013;65(5)633-43.
  • Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol 2011;8:207–12.
  • Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. NHS Cancer Screening Programmes, 2009.
  • Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res 2011;13;4(4):486–501.
  • Castro E, Eeles R. The role of BRAC1 and BRAC2 in prostate cancer. Asian J Androl 2012;14(3):409-14.
  • Clearinghouse TNNK and UDI. Prostatitis: Disorders of the Prostate. 2013. Available from:
  • Colin SM, Metcalfe C, Donovan J, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen detected localized and advanced prostate cancer: a case-control study nested within the UK based population ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008;102(10):1400-40.
  • Crawford E D. Understanding the Epidemiology, Natural History and Key Pathways Involved in Prostate Cancer. 2009 Urology;73:5A
  • Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23(7):1665–71.
  • Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60(4):809-25.
  • Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis. J Natl Cancer Inst 2005;97(23):1768-77.
  • Giovannucci E, Liu Y, Platz EA, et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121(7):1571-8.
  • Ho T, Gerber L, Aronson WJ, et al. Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. Eur Urol 2012;62(5):910–6.
  • Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-94.
  • Kirby M, Chapple C, Jackson G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract 2013;67(7):606-18.
  • Lifetime risk of cancer. Cancer Research UK. 2010. Available
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med 2015;13(1):171
  • Ma RW, Chapman K. A systematic review of the effect of diet in prostate cancer prevention and treatment. J Human Nutrition and Dietetics 2009;22(3):187-99.
  • McNaughton-Collins M, Joyce GF, Wise M, et al. Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Publishing Office, 2007; NIH Publication No. 07-5512 pp. 9-42.
  • McPherson K, Steel CM, Dixon JM. ABC of Breast Diseases. Breast cancer: epidemiology, risk factors and genetics. BMJ 2000;321:624–8.
  • Mitra AV, Bancroft EK, Barbachano Y, et al Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2010;107:28-39.
  • Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology. April 2014
  • NICE. Guideline for management of lower urinary tract symptoms in men. NICE Clinical guideline 97. May 2010.
  • Orsini N, Bellocco R, Bottai M, et al. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 2009;101(11):1932-8.
  • Popiolek M, Rider JR, Andren O, et al. Natural history of early, localized prostate cancer: A final report from three decades of follow-up. Eur Urol 2013;63(3):428-35.
  • Prostate cancer incidence statistics. Cancer Research UK. 2011. Available from:
  • Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. Evidence document January 2010.
  • Prostate cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence (NICE). January 2014. Clinical guideline 175.
  • Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101(3):17-21.
  • Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013;64(6):981–87.
  • Shephard EA, Stapley S, Neal RD, et al. Clinical features of bladder cancer in primary care.  Br J Gen Pract 2012;62(602):e598-604.
  • Speakman M, Kirby R, Doyle S, Loannau C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK. BJU Int 2014
  • Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2012;110(7):1014–22.
  • Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94(18):1358-65.
  • Trueman P, Hood SC, Nayak USL et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999;83:410-15.
  • Walsh AL, Considine S, Thomas AZ, et al. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract 2014.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication